Verve Therapeutics, Inc.
DelistedCIK 1840574fmd_18CGTGNYSABE71EWZ8FJE53ZKBManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Mar 31, 2025, 22 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Research and development | 11 | 35 | 68 | 130 | 185 | 204 |
| Total operating expenses | 14 | 41 | 87 | 168 | 235 | 261 |
| Operating income | (14) | (41) | (87) | (166) | (223) | (229) |
| Other non-operating income (expense) | (6) | (5) | (33) | 8 | 23 | 30 |
| Income before taxes | – | (46) | (120) | (157) | (200) | (198) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (46) | (120) | (157) | (200) | (199) |
| Net income | (19) | (200) | (120) | (157) | (200) | (199) |
| Net income to common shareholders | (19) | (46) | (120) | (157) | (200) | (199) |